RxDoctor Payments Data

Daniel Dansdill, MD

Ophthalmology · Phoenix, AZNPI 1013449024

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.4% of the total across 290 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Alcon at 33.3% of the total.

$9,175in general payments, 2019–2025

Across 290 payments — averaging $31.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • AbbVie$2K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
  • Sight Sciences, Inc.$1K
  • Glaukos Corporation$704
  • Bausch & Lomb Americas Inc.$321
  • plus $1K from 9 others

What the payments were for

  • Travel & lodging$88310%
  • Food & beverage$8,29290%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,175 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$379,827
Medicare patients
539
Services billed
2,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate277$141,927
LumiganBimatoprost199$93,323
VyzultaLatanoprostene Bunod90$44,228
RocklatanNetarsudil Mesylat/Latanoprost83$40,335
Prednisolone Acetate793$33,586
SimbrinzaBrinzolamide/Brimonidine Tart102$31,027
Latanoprost1,619$19,875
Alphagan PBrimonidine Tartrate39$19,693
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat1,071$19,469
Brimonidine Tartrate916$18,245
CombiganBrimonidine Tartrate/Timolol36$16,215
Dorzolamide Hcl376$9,849
RestasisCyclosporine12$9,758
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol50$9,288
Travoprost47$6,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan, Restasis$1,576$138,989286 claims
Bausch & Lomb Americas Inc.Vyzulta$321$44,22890 claims
AlconSimbrinza$3,059$31,027102 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →